Hemostemix Announces Two Additional Sites Enrolled in Phase

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
34
Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial

CALGARY, Alberta, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from two new medical centers to be clinical trial sites for the Company’s Phase II clinical trial for critical limb ischemia (“CLI”).  In addition, the Company is pleased to provide an update on patient enrollment in the trial.

Medical University of South Carolina is located in Charleston, South Carolina, USA with Dr. Thomas E. Brothers, MD as the principal investigator.  Dr. Brothers is a vascular surgeon who focuses on management of circulation and peripheral vascular disease and has been recognized as one of America’s top surgeons and best doctors since 2003.  Founded in 1824, the Medical University of South Carolina (“MUSC”) educates and trains more than 3,000 students and 700 residents in six colleges and has nearly 13,000 employees, including approximately 1,500 faculty members.  MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the NCI-designated Hollings Cancer Center, a Level I trauma centre and South Carolina’s only transplant center.

Moses H. Cone Memorial Hospital (“MCMH”) is located in Greensboro, North Carolina, USA with Dr. Vance Wells Brabham IV, MD as principal investigator.  Dr. Brabham is a board-certified surgeon who specializes in vascular surgery. His professional interests include complex aortic repair, carotid disease, minimally invasive and surgical treatment of peripheral vascular disease, and venous disease.  MCMH is the largest and most comprehensive medical center within its five-county region with a 63-acre campus including a 536-bed teaching hospital and referral center.  One of its featured services is the Cone Health Heart Vascular Center. The MCMH has been recognized for heart and vascular care and focuses on clinical trials that have high potential for advancing treatment of heart and vascular disease.

With the addition of these two new sites, the Company has a total of eleven trial sites now open for patient enrollment, of which ten are located in the United States and one in Vancouver, Canada.  All sites are actively screening patients for enrollment in the study.  In addition, the Company also has seven clinical trial sites located in Canada and the United States that are in various stages of the on-boarding process. The Company specifically targets strategic clinical sites throughout the United States and Canada that serve large populations or have the demographics to support patient enrollment. 

Currently a total of twenty four (24) patients have been treated under the clinical trial to-date. The Company anticipates that patient enrollment will escalate rapidly with these additional trial sites on-boarded.   

The clinical trial is a randomized, placebo-controlled, double blind Phase II clinical trial to confirm the safety and efficacy of ACP-01. Under the current USA Food and Drug Administration (“FDA”) and Health Canada approved protocol approximately 95 patients will be followed for a minimum period of six months and a maximum of twelve months. The Company’s patented process results in specific stem cells that have the ability to support the generation of new blood vessels to combat the life-threatening complications of CLI. The stem cells are differentiated and expanded from the patient’s blood and then re-injected into the diseased tissue.

“We are excited with the progress we have made on the trial with these two key trial sites located in North and South Carolina being recently on-boarded. Both of these sites have recognized heart and vascular centers with leading vascular surgeons acting as principal investigators. The escalation in site enrollment is a positive indication of the interest in our trial and the need for new treatments for CLI that could offer an alternative to life altering amputations which is currently one of the limited treatment options available for some CLI sufferers,” states Kyle Makofka, President and CEO of Hemostemix.  

ABOUT HEMOSTEMIX INC.

Hemostemix is a publicly traded clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is one of the first clinical-stage biotech companies to test a stem-cell therapy in an international, multicenter, Phase II clinical trial for patients with critical limb ischemia (“CLI”), a severe form of peripheral artery disease (“PAD”) caused by reduced blood flow to the legs. The Phase II trial targets a participant’s diseased tissue with proprietary cells grown from his or her blood that can support the formation of new blood vessels. The Company’s intellectual property portfolio includes over 50 patents issued or pending throughout the world.  Hemostemix has a manufacturing contract with Aspire Health Science, LLP (“Aspire”), for the production of ACP-01 and for research and development purposes at Aspire’s Orlando, Florida, facility.  Building towards commercialization, Hemostemix has also licensed the use, sale and import of ACP-01 for certain indications to Aspire in certain jurisdictions. The Company is continuing research and development of its lead product, ACP-01 with other applications, including cardiovascular, neurological and vascular indications.

For more information, please visit www.hemostemix.com or email office@hemostemix.com .

Contact:

Kyle Makofka, President and CEO Suite 1049, 150 – 9 th Avenue S.W. Calgary, Alberta T2P 3H9 Phone: (403) 506-3373 E-Mail: kmakofka@hemostemix.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,”  “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s stage of development, future clinical trials and results, long-term capital requirements and future ability to fund operations, future developments in the Company’s markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Company’s operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 225

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 55

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 136

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 29

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Agriculture with Mainstay® Calcium 2.0 Certification

Updated Category News Views 105

Mainstay® Calcium 2.0 Achieves Certification Mainstay® Calcium 2.0 has earned its rightful place as a certified biostimulant, revolutionizing the agricultural landscape. This exciting development marks a significant milestone in enhancing crop health and productivity, driven by advanced agricultural research and innovation. The Importance of Biostimulants in Farming In...

Continue Reading
Discover the Impressive Growth of Viper Energy Stock Over Time

Updated Category News Views 132

Understanding Viper Energy's Stock Growth Viper Energy Inc (NASDAQ: VNOM) has demonstrated impressive performance over the last five years, surpassing the general market by a notable margin. With an annualized growth rate of 15.74%, the company has generated an average annual return of 30.08%. As it stands, Viper Energy boasts a market capitalization of approximately...

Continue Reading
Synthetic Rope Market Growth Driven by Diverse Applications

Updated Category News Views 244

Synthetic Rope Market Dynamics The global synthetic rope market is projected to experience significant growth, with estimates suggesting it could reach USD 3.07 billion by 2029. This growth is fueled by a compound annual growth rate (CAGR) of 6.7% from 2024 to 2029. Various applications across industries such as marine, fishing, oil & gas, as well as sports and leisure...

Continue Reading
Innovative Keg Cover Promises Convenience for Beer Lovers

Updated Category News Views 168

Introducing the HUG-A-BARREL: A Game-Changer for Events The HUG-A-BARREL is an innovative invention that transforms the way beer lovers enjoy their drinks during outdoor gatherings. Imagine a specially designed covering for beer kegs that not only keeps your favorite brews cold for hours but also eliminates the messy task of filling up a tub with ice. This invention is...

Continue Reading
Global Innovations Highlighted at the Successful COMEUP 2025 Festival

Updated Category News Views 116

Celebrating Success at COMEUP 2025 COMEUP 2025 wrapped up successfully, showcasing a blend of innovation and collaboration among startups from around the globe. This annual festival, organized by the Ministry of SMEs and Startups in South Korea, provided an invaluable platform for entrepreneurs to connect, collaborate, and innovate under the inspiring theme "Recode the...

Continue Reading